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Abstract
Background Currently, the number of patients with SARS-COV-2 infection has increased rapidly in Iran, but the risk and
mortality of SARS-COV-2 infection in Iranian patients with diabetesmellitus (DM), chronic kidney disease (CKD), hypertension
and cardiovascular diseases (CVDs) still not clear. The aim of this meta-analysis was to estimate the proportion and mortality of
SARS-COV-2 in these patients.
Methods A comprehensive literature search was carried out in PubMed, Web of Sciences, Cochrane Library, EMBASE, CNKI,
SciELO, and other databases to identify all relevant studies published up to 10 January, 2020. The proportion and mortality in the
patients were assessed by odd ratio (OR) and the corresponding 95% confidence interval (95% CI).
Results A total of ten case-series including 11,755 cases with SARS-COV-2 infection and 942 deaths were selected. Among
them, there were total of 791 DM patients with 186 deaths, 225 CKD patients with 45 deaths, 790 hypertension cases with 86
deaths, and 471 CVDs cases with 60 deaths. Pooled data revealed that the proportion of SARS-COV-2 infection in the patients
with hypertension, DM, CVDs and CKD were 21.1%, 16.3%, 14.0% and 5.0%, respectively. Moreover, the SARS-COV-
2 infection were associated with an increased risk of mortality in DM (OR = 0.549, CI 95% 0.448–0.671, p ≤ 0.001) and CKD
(OR = 0.552, 95% CI 0.367–0.829, p = 0.004) patients, but not hypertension and CVDs. There was no publication bias.
Conclusions Our pooled data showed that the proportion of SARS-COV-2 infection was the highest in the Iranian patients with
hypertension (21.1 %) followed by DM (16.3%), CVDs (14.0 %) and CKD (5.0%). Moreover, DM and CKD in patients with
SARS-COV-2 infection were associated with a 0.549 and 0.552-fold increase in mortality, respectively. Clinicians in Iran should
be aware of these findings, to identifying patients at higher risk and inform interventions to reduce the risk of death. Moreover,
well-designed, large-scale and multicenter studies are needed to improve and validate our findings.
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Introduction
Coronavirus disease 2019 (COVID-19) caused by 2019 novel
coronavirus (2019-nCoV) has caused significant mortality
and has been declared as a global pandemic by the World
Health Organization [1–5]. COVID-19 is a major public
health concern and one of the leading cause of mortality in
most countries [6–8]. At the time this paper is written,
COVID-19 has inflicted more than 55.4 million people glob-
ally and causing more than 1.3 death to date with overall
mortality rate of 2.4 % [9]. Based on official reports of Iran
about 788,473 people infected and have surpassed 42,461
deaths up to November 17, 2020 [10]. The main reason for
death due to SARS-COV-2 infection has been described and
pre-existing comorbidities significantly increase the disease
mortality [11, 12].
About 20–51% of patients hospitalized with SARS-COV-
2 infection are found to have at least one comorbid condition
[13]. In patients with COVID-19, underlying disease such as
diabetes mellitus (DM), chronic kidney disease (CKD), hy-
pertension, cardiovascular diseases (CVDs), and other chronic
diseases are associated with a higher risk of severe complica-
tions, death and may be associated with a rapid progression
and poor prognosis of SARS-COV-2 infection [14–18]. To
date, several clinical and epidemiological studies have indi-
cated higher risk of SARS-COV-2 infection in DM patients
[19, 20]. However, it is not yet known whether patients with
underlying DM are more susceptible to SARS-COV-
2 infection [21–23]. Some studies postulated that the angio-
tensin converting enzyme 2 (ACE2) may be the plausible
explanation of the association between risk of SARS-COV-
2 infection in DM, CKD and CVDs patients and COVID-19
severity [24–26]. Moreover, diabetic individuals have a great-
er risk of respiratory infections due to compromised immune
system, especially the innate immunity [27–29].
Previous studies have indicated that CKD patients with
SARS-CoV-2 infection are vulnerable to be infected and
become sever, since SARS-CoV-2 enters lung cells
through the ACE2 receptor [30].
The link between underlying disease such as DM, CKD,
hypertension and CVDs and SARS-COV-2 infection out-
comes was reported in number of studies in Iran but its exact
prevalence is still unclear [16, 31, 32]. Moreover, the data on
the risk and mortality of SARS-COV-2 infection associated
with these underlying conditions are conflicting [31]. The ac-
tual burden of these underlying diseases in Iran is consider-
able. Understanding the relationship between risk and mortal-
ity of SARS-COV-2 infection and country of origin of these
patients is an urgent research priority, in order to reduce the
disproportionate burden of disease. Recently there has been an
increase in the literature on clinical outcome and demograph-
ical data of SARS-COV-2 infection in Iran. However, most
available data sources were based on case series or small
cohorts, limiting their results. Thus, this meta-analysis was
carried out to estimate the proportion and mortality of
SARS-COV-2 infection among Iranian patients with DM,
CKD, hypertension, and CVDs.
Materials and methods
Search strategies
We carried out a meta-analysis in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines (http://www.
prismastatement.org). We have performed a comprehensive
computer bibliographic search on PubMed/MEDLINE,
Google Scholar, EMBASE, Cochrane Library database,
SciELO, Springer Link, Chinese Biomedical Database
(CBD), China National Knowledge Infrastructure (CNKI)
platforms, VIP, Chinese literature (Wan Fang) and China
Science and Technology Journal database and Egyptian
Knowledge Bank (EKB) Journals to identify all relevant stud-
ies assesse the risk and mortality of SARS-CoV-2 infection in
DM, CKD, hypertension and CVDs patients up to 10 January,
2020. The following medical subject headings (MeSH) terms
and keywords to search: (‘’COVID-19 virus disease’’ OR
‘’Severe Acute Respiratory Syndrome Coronavirus 2’’ OR
‘’SARS-CoV-2’’ OR ‘’2019 novel coronavirus infection’’
OR ‘’2019-nCoV infection’’ OR ‘’coronavirus disease’’
2019 OR ‘’coronavirus disease-19’’ OR ‘’2019-nCoV dis-
ease’’ OR ‘’COVID-19 virus infection’’) AND (‘’Death’’
OR ‘’Mortality’’ OR ‘’Fatal Outcome’’ OR ‘’Fatal
Outcomes’’ OR ‘’Outcome’’) AND (‘’Comorbidities’’ OR
‘’Underlying Disease’’) AND (“Diabetes Mellitus” OR
‘’Glucose Intolerance’’ OR’’ Insulin Resistance’’ OR ‘’
Glucose’’ OR ‘’Blood Glucose’’ OR ‘’Blood Sugar’’ OR
‘’Hyperglycemia’’ OR ‘’Hyperglycemias’’ OR ‘’Metabolic
Cardiovascular Syndrome’’ OR ‘’Cardiovascular
Syndrome’’ OR ‘’Metabolic Cardiovascular’’) AND
(‘’Hypertension’’ OR ‘’HTN’’ OR ‘’HT’’ OR ‘ high blood
pressure’’ OR ‘’HBP’’) AND (‘’Chronic Kidney Disease’’
OR ‘’Renal Disease’’ OR ‘’Renal Injury’’) AND (‘’
Cardiovascular disease’’ OR ‘’Coronary artery disease’’ OR
‘’coronary heart disease’’OR ‘’ischemic heart disease’’OR ‘’
heart disease’’). We restricted our search to human studies.
But, there was language restriction in this meta-analysis to
Persian and English language publications. In addition, we
manually screened references of relevant publications and re-
views for additional relevant articles. Articles included in the
meta-analysis published in the primary literature and had no
obvious overlap of subjects with other studies. Considering
that this study was a meta-analyses and systematic review, an
Institutional Review Board approval was not required.
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Inclusion and exclusion criteria
The full text of primary studies was selected according to the
following inclusion and exclusion criteria: (1) primary case
series and case-control publications; (2) studies evaluated clin-
ical characteristics and outcome of SARS-CoV-2 infection
Iranian patients with diabetesmellitus, chronic kidney disease,
hypertension and cardiovascular disease; (3) studies reported
mortality of SARS-CoV-2 infection Iranian patients with dia-
betes mellitus, chronic kidney disease, hypertension and car-
diovascular disease; and (4) sufficient data were presented to
calculate the odds ratio (OR) with 95% confidence interval
(CI). In addition, the following exclusion criteria were also
used: (1) insufficient data; (2) non-human or in vitro studies;
(3) non-consecutive case series; (4) abstracts, case report,
posters, editorials, reviews, conference papers, and previous
meta-analyses and non-standard data presentation; and (5)
overlapping and duplicated data.
Data extraction
Two authors independently reviewed all titles and abstracts of
the selected studies in the primary search and extracted the
necessary data into a standardized form. When the authors
were not in agreement, a third author was involved to reach
an agreement. All necessary data were extracted conforming
to the standardized extraction checklist for the following data:
name of first author, year of publication, city or province,
mean age, study type, total numbers of infected cases and
mortality, total numbers of infected cases and mortality in
DM, CKD, hypertension, and CVDs patients. If a duplicate
publication was found or the same population was used in
multiple studies, the publication with the larger sample size
was included in the meta-analysis. The corresponding author
was contacted through email for any missing data.
Quality score assessment
The Newcastle-Ottawa Score (NOS) were performed to assess
the quality of included studies in the meta-analysis and to
assess the various aspects of the methodology used by the
observational research, which are relevant to the quality of
the study. This standard assessed 3 sections (selection of
cases, comparability of groups, and determination of expo-
sure) and 8 items. In the selection and exposure categories, a
quality research item received 1 star, and a comparable cate-
gory could receive at most 2 stars. The quality assessment
values ranged from 0 stars (worst) to 9 stars (best). Thus, the
studies were divided into three groups: higher quality score ≥
7; moderate quality 4 ≤ score < 7; low quality score < 4.
Generally, the study which scored at least 5 points was con-
sidered to be included in meta-analysis and any discrepant
opinions were resolved by discussion and consensus.
Statistical analysis
The proportion and mortality of SARS-COV-2 infection in
Iranian patients with DM, CKD, hypertension and CVDs
was assessed by odds ratios (ORs) with 95% confidence in-
tervals (CIs). The significance of pooled ORs was determined
using the Z-test, in which P < 0.05 defined as the significance
threshold. A between-study heterogeneity was tested using the
Q-statistic test, which P ≤ 0.10 indicated significant heteroge-
neity a crossing studies. Moreover, the I2 statistic was used to
qualify the heterogeneity (range of 0 to 100%: I2 = 0–25%,
no heterogeneity; I2 = 25–50%, moderate heterogeneity; I2 =
50–75%, large heterogeneity; I2 = 75–100%, extreme hetero-
geneity). If between-study heterogeneity existed statistically, a
random effect model (DerSimonian and Laird method) was
adopted; otherwise, affixed effect model (Mantel-Haenszel
method) was used in the absence of heterogeneity [33–35].
A visual inspection of the funnel plot was used to assess po-
tential publication bias. Moreover, Egger’s test was performed
to assess the publication bias statistically, in which p < 0.05
was considered statistically significant. If the publication bias
tests indicated bias existed, the Duval and Tweedie ‘‘trim and
fill’’ method was used to adjust the bias. All of the statistical
calculations were performed using Comprehensive Meta-
Analysis (CMA) software version 2.0 (Biostat, USA). Two-
sided P-values < 0.05 were considered statistically significant.
Results
As shown in Fig. 1, a total of 528 articles were yield
from the databases up to 10 January, 2020, but 287
were excluded because of duplication. Then, the titles
and abstracts of the articles were checked, and 129 were
excluded because they did not meet our inclusion
criteria. After the full text of the articles was read,
119 were excluded due to irrelevance to the current
meta-analysis scope, and/or were case reports, reviews,
previous meta-analyses, and other disease or lack of the
relevant data. Finally, a total of ten publication includ-
ing 11,755 infected cases with 942 deaths were selected
[14, 36–44]. The study characteristics of included stud-
ies in the present meta-analysis are described in
Table 1. Among them, there were total of 791 DM
patients with 186 deaths, 225 CKD patients with 45
deaths, 790 hypertension cases with 86 deaths, and
471 CVDs cases with 60 deaths. All included publica-
tions were retrospective case-series studies. The studies
were performed in Fars, Tehran, Mazandaran and
Alborz provinces. All selected studies were published
in English between June 2020 and January 2021. The
NOS score of the included studies was 7–9, and the
quality of the articles was evaluated as high (Table 1).
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Quantitative data synthesis
Diabetes mellitus
The summary of proportion and mortality in the Iranian DM
patients with SARS-COV-2 Infection are presented in Table 2.
For the analysis of proportion of SARS-COV-2 Infection, a total
of eight studies with 615 DM patients were included. There was
a significant heterogeneity, thus a random-effect meta-analysis
was to estimate an OR for proportion of SARS-COV-2 Infection
inDMpatients. The combined results showed that the proportion
of SARS-COV-2 infection in Iranian DM patients was 16.3%
(95% CI 0.085–0.291, p ≤ 0.001, Fig. 2a). For the analysis of
mortality, eight studies with 132 reported deaths in DM patients
were selected. A fixed-effects analysis showed a pooled ORs of
0.549 (95% CI 0.448–0.671, p ≤ 0.001, Fig. 2b).
Chronic kidney disease
The summary of proportion and mortality in the Iranian
CKD patients with SARS-COV-2 Infection are presented
in Table 2. For the analysis of proportion of SARS-COV-
2 Infection, a total of seven studies with 195 CKD pa-
tients were included. There was a significant heterogene-
ity, thus a random-effect meta-analysis was to estimate an
OR for risk of infection in CKD patients. Pooled data
showed that the proportion of SARS-COV-2 Infection in
the CKD patients was 5.0 % (95 % CI 0.019–0.124, p ≤
0.001, Fig. 3a). For the analysis of mortality, six studies
with 39 deaths in CKD patients were included. A fixed-
effects analysis showed a pooled ORs of 0.552 (95 % CI
0.367–0.829, p = 0.004, Fig. 3b).
Fig. 1 The study selection and inclusion process
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Hypertension
The summary of proportion and mortality in the Iranian hy-
pertension patients with SARS-COV-2 Infection are present-
ed in Table 2. For the analysis of proportion of SARS-COV-2
Infection, a total of eight studies with 564 cases with hyper-
tension were included. There was a significant heterogeneity,
thus a random-effect meta-analysis was to estimate an OR for
proportion of infection in hypertension patients. Pooled data
revealed that the proportion of SARS-COV-2 Infection in the
hypertension patients was 21.1% (95% CI 0.102–0.387, p =
0.003, Fig. 4a). For the analysis of mortality, six studies with
49 deaths in patients with hypertension were selected. A
fixed-effects analysis showed a pooled ORs of 0.942 (95%
CI 0.720–1.234, p = 0.666, Fig. 4b).
Cardiovascular disease
The summary of proportion and mortality in the Iranian CVDs
patients with SARS-COV-2 Infection are presented in
Table 2. For assessment of proportion of SARS-COV-
2 infection in CVD patients, a total of eight studies with 353
cases with CVD were included. There was a significant het-
erogeneity, thus a random-effect meta-analysis was to esti-
mate an OR for proportion of infection in hypertension pa-
tients. Pooled data revealed that the proportion of SARS-
COV-2 Infection in the CVD patients was 14.0% (95% CI
0.058–0.301, ≤ 0.001, Fig. 5a). For the analysis of mortality,
six studies with 41 deaths in patients with CVDwere selected.
A fixed-effects analysis showed a pooled ORs of 0.838 (95%
CI 0.610–1.151, p = 0.275, Fig. 5b).
Heterogeneity test
Table 2 listed the main results of between-study heterogeneity
for proportion and mortality in the infected patients with
COVID-19. The analyses provide an important visualization
of the data available, and highlight the between-study hetero-
geneity for proportion in the Iranian patients with DM (I2 =
98.83, Ph≤0.001), CKD (I2 = 97.51, Ph≤0.001), hypertension
Fig. 2 Forest plots for proportion (a) and mortality (b) in the Iranian diabetes mellitus patients with SARS-COV-2 Infection
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(I2 = 98.89, Ph≤0.001) and CVDs (I2 = 98.75, Ph≤0.001).
However, there was no significant heterogeneity for mortality
in the patients with SARS-COV-2 infection. Thus, need to
improve data collection and analysis, including greater stan-
dardization in adjusted analyses. The heterogeneity in whole
population and subgroups was shown in Table 2.
Sensitivity analysis
A sensitivity analysis is an important part of a meta-analysis to
evaluate the robustness of the pooled data to the assumptions
made in performing the analysis [45]. Thus, we performed
sensitivity analysis of the summary ORs by sequential remov-
al of each study to assess the stability of our findings. Results
revealed that none of the studies changed the pooled OR for
proportion and mortality in Iranian DM, CKD, hypertension,
and CVDs patients with SARS-COV-2 Infection. Taken to-
gether, these results suggested that the our findings were ro-
bust and stable.
Publication bias
The most commonly used method to evaluate a dataset for
potential publication bias in a meta-analysis is via the con-
struction of funnel plots [45]. We performed Funnel plot and
Egger’s linear regression test to detect publication bias. The
shapes of the funnel plots did not reveal evidence of obvious
asymmetry in all comparison models. Moreover, the Egger’s
test was used to provide statistical evidence of publication
funnel plot symmetry. No obvious evidence of publication
bias was revealed by the results (Table 2). Figure 4 showed
the funnel plots for proportion (Fig. 6a–d) and mortality (Fig.
7a–d) of SARS-COV-2 infection in Iranian patients with dia-
betes mellitus, chronic kidney disease and hypertension,
respectively.
Discussion
Several previous single studies and meta-analyses indicated
that DM, CKD, hypertension and CVD might be risk factor
and promoter of severity and mortality for SARS-COV-
2 infection [26]. It is possible that mechanism mediated by
ACE2 receptor links patients with these underlying diseases
with a higher risk of SARS-COV-2 infection and death [31,
46, 47]. To date, some studies evaluated the proportion and
mortality of SARS-COV-2 infection in the Iranian DM, CKD,
hypertension and CVD patients. To our knowledge, this is the
first meta-analysis to assess the proportion and mortality of
SARS-COV-2 infection in the Iranian DM, CKD, hyperten-
sion and CVD patients. Our combined data based on ten stud-
ies with 11,755 infected cases and 942 deaths showed that the
Fig. 3 Forest plots for proportion (a) and mortality (b) in the Iranian chronic kidney disease patients with SARS-COV-2 Infection
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proportion of SARS-COV-2 infection in the Iranian DM, CKD,
hypertension and CVD patients were 21.1%, 16.3%, 14.0%
and 5.0%, respectively. Moreover, the pooled ORs revealed that
there was significant correlation between mortality and SARS-
COV-2 infection in the Iranian DM and CKD patients.
The link between risk and COVID-19 outcomes and
SARS-COV-2, Severe Acute Respiratory Syndrome (SARS-
CoV) and Middle East Respiratory Syndrome (MERS-Cov)
infection was previously reported in single studies and meta-
analyses worldwide [21, 48, 49]. It is well known that all-
cause mortality rate in patients with DM is higher than in
patients without DM [50–52]. Our pooled data showed that
the proportion of SARS-COV-2 infection in the Iranian pa-
tients with DM was 16.3%. Moreover, our findings showed
that the SARS-COV-2 infection was associated with an in-
creased risk of mortality in the DM patients. We found a
0.549-fold increase in mortality associated with SARS-
COV-2 infection in Iranian patients with DM (Table 2). de
Almeida-Pititto et al., in a meta-analysis with a total of 4305
cases with 564 DM demonstrated a 2.3-fold increase in the
risk of severity and a 2.5-fold increase in mortality associated
with SARS-COV-2 infection in those patients worldwide
[31]. Huang et al., in a meta-analysis of 30 studies with
6452 patients revealed that the DM was associated with poor
outcome of the COVID-19. Their results showed that DMwas
associated with higher mortality rate in in patients with
COVID-19 pneumonia. However, DM was not associated
with increased need for ICU care [53]. Moreover, Kumar
et al., in a meta-analysis of 33 studies (16,003 cases) found a
1.90-fold increase for DM mortality among people with
SARS-COV-2 infection [32]. Barron et al., in nationwide
analysis in England in patients with SARS-COV-2 infection
between March 1 and May 11, 2020 reported that patients
with DM was associated with significantly increased ORs of
in-hospital death with COVID-19. Moreover, their results re-
vealed that DM status, age, gender, ethnicity, and deprivation
were potential confounding factors in the mortality of those
patients [54]. Singh et al., in a meta-analysis based on 18
studies with 14,558 cases reported that the pooled prevalence
for comorbidities in patients with COVID‐19 disease was
10% for CVDs, 11% for DM, and 23% for hypertension.
They described that CVDs, DM and hypertension significant-
ly increased the risk of severe COVID‐19 [18]. Barron et al.,
revealed that DM patients with COVID-19 had 3.5 and 2.0
times higher mortality in hospital compared to those without
DM, and this was attenuated to 2.9 and 1.8 when adjusted for
previous hospital admissions with coronary heart disease, ce-
rebrovascular disease or heart failure in UK [54].
Fig. 4 Forest plots for proportion (a) and mortality (b) in the Iranian hypertension patients with SARS-COV-2 Infection
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Previous studies have described that there is the involve-
ment of kidneys with SARS-COV-2 infection which might be
caused high mortality [55, 56]. It has been suggested that
CKD in patients with SARS-COV-2 infection might be
caused by synergistic effect of virus-induced direct cytotropic
effect and cytokine-induced systemic inflammatory response
[57]. In the current meta-analysis, the proportion of SARS-
COV-2 infection in the Iranian patients with DM was 16.3%.
Moreover, our findings showed that the SARS-COV-
2 infection was associated with an increased risk of mortality
in the CKD patients. Moreover, it was associated with 0.552-
fold increase of mortality among Iranian infected patients with
SARS-COV-2 (Table 2). Cai et al., in a meta-analysis based
12 studies with 3,867,367 cases described that the mortality
rate among CKD patients with SARS-COV-2 infection was
significantly higher that CKD patients without SARS-COV-
2 infection (OR = 5.81; 95% CI 3.78–8.94, P ≤ 0.001). They
suggested that the major reason is that the levels of pro-
inflammatory cytokines are increased in the CKD infected
patients and leads to an increase in oxidative stress that even-
tually produces an inflammatory immune response [58].
Moreover, they have shown that CKD was significantly asso-
ciated with an increased risk of mortality in elderly (≤ 70)
infected patients. Kolhe et el., in a study among 1,161 UK
infected with COVID-19 patients showed a high incidence
of acute kidney injury (AKI) in patients with SARS-COV-
2 infection which is associated with a 3 fold higher ORs of
mortality than infected patients without AKI and a 4-fold
higher odds of death than AKI due to other causes [55].
It appears that hypertension is a risk factor for severe form
of SARS-COV-2 infection [59]. CVDs are frequent in SARS-
COV-2 infection, and might contribute to severe forms of
COVID-19 and mortality [60]. However, the mechanism im-
plicated in the association between severity or mortality of
SARS-COV-2 infection and CVD is still under investigation.
Potential explanations include the high prevalence of cardio-
vascular disease in older people (another established risk fac-
tor for adverse outcome), a functionally impaired immune
system, and an elevated angiotensin converting enzyme-2
(ACE2) receptor expression. Our pooled ORs revealed that
the proportion of SARS-COV-2 infection in Iranian patients
with CVDs was 14.0%, respectively. However, there was no
significant association between mortality in the patients with
CVDs and COVID-19 (Table 2). Hessami et al., in a meta-
analysis including 159,698 COVID-19 patients reported a
high burden ofCVDs in patientswith SARS-COV-2 infection,
which was significantly associated with mortality and ICU
admission [61]. Moreover, in the current meta-analysis, we
found that the proportion of SARS-COV-2 infection in
Iranian patients with hypertension was 21.1 %. However,
pooled data revealed that the SARS-COV-2 infection was
not associated with an increased risk of mortality in the hy-
pertension patients (Table 2). A study revealed a significantly
increased risk of adverse outcomes in CVDs patients with ~
Fig. 5 Forest plots for proportion (a) and mortality (b) in the Iranian cardiovascular disease patients with SARS-COV-2 Infection
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15 to 70% of COVID-19 related deaths [62]. However, a
previous meta-analysis described that COVID-19 has a higher
mortality and case fatality rate and has increased risk of ad-
verse outcomes in patients with underlying CVDs [62]. Singh
et al., in a meta-analysis revealed that the CVDS increased the
risk of mortality in patients SARS-COV-2 infection [18]. A
study in Hubei province among 44 672 confirmed cases with
COVID-19 reported that infected patients without any
Fig. 6 Begg’s funnel plot for publication bias test for proportion of SARS-COV-2 infection in Iranian patients with diabetes mellitus (a), chronic kidney
disease (b), hypertension (c) and cardiovascular disease (d)
Fig. 7 Begg’s funnel plot for publication bias test for mortality of SARS-COV-2 infection in Iranian patients with diabetes mellitus (a), chronic kidney
disease (b), hypertension (c) and cardiovascular disease (d)
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underling disease had a case fatality rate of 0.9 %, rising to
6% in patients with hypertension, 7 % in patients with diabe-
tes and 10% in patients with CVDs [63].Momtamanesh et al.,
in meta-analysis based on 35 studies revealed that CVDs oc-
curred in more than 25% of infected cases with SARS-COV-
2, mortality was 20 times higher, and admission to ICU in-
creased by 13.5 times. They have demonstrated that CVDs are
common in patients with SARS-COV-2 infection and are as-
sociated with increased severity and mortality in these patients
[64]. We suggested that these patients might have used ACE
inhibitors and ARBs which reduced mortality of SARS-COV-
2 infection. Hippisley-Cox et al., revealed that ACE inhibitors
were associated with a significantly reduced risk of SARS-
COV-2 infection requiring hospital admission, but were not
significantly associated with risk of ICU care [65]. Previous
studies indicated that the association between hypertension
and worse outcomes of SARS-COV-2 Infection may be due
to the higher proportion of comorbidities and amore advanced
age of these patients. Pranata et al., in a meta-analysis revealed
that hypertension was associated with increased mortality and
COVID-19 severity [31]. However, Iccarino et al., reported
that hypertension was not an independent factor affecting the
SARS-COV-2 Infection in Italian patients [66].
It should be noted that the current meta-analysis has some
limitation which should be considered. First, all included ar-
ticles included in this study published in English-language
journals, which might lead to language bias and studies issued
in other languages and unpublished studies might be missed.
Second, the numbers of studies as well as sample sizes in
some studies were relatively limited, which Type-II error
might not be dismissed and influenced reliability of this
meta-analysis findings. Third, a study included in the current
meta-analysis involved data that had not been peer reviewed.
However, inclusion of preprint studies helped to provide a
broader views of the emerging literature, in a rapidly evolving
field. Fourth, the current meta-analysis was performed in
Iranian patients, which may have led to the selection bias.
Moreover, these results cannot be generalized to other popu-
lations. Fifth, the small number of only ten studies indicated
that the statistical power to detect differences was suboptimal.
However, the pooled results in our review were more reliable
than the results in each of the individual studies. Finally, mul-
tivariate analysis for adjusting the several confounding factors
such as age and gender that could have an effect on results was
not performed due to insufficient data in most studies. Thus, a
more precise analysis stratified by clinical manifestation
would require further evaluation.
In summary, this study presents a literature review and
meta-analysis of the information reported so far on the pro-
portion and mortality rate of Iranian DM, CKD, hypertension,
and CVDs patients with SARS-COV-2 infection. Our pooled
data revealed that the proportion of SARS-COV-2 infection
was the highest in the Iranian patients with hypertension
(21.1 %) followed by DM (16.3 %), CVDs (14.0 %) and
CKD (5.0%). Moreover, DM and CKD in the Iranian patients
with SARS-COV-2 infection were associated with a 0.549
and 0.552-fold increase in mortality, respectively. Clinicians
in Iran should be aware of these findings, to identify patients at
higher risk and inform interventions to reduce the risk of
death. However, multicenter and well-designed studies with
larger sample size are needed to improve our findings and to
provide a higher level of evidence.
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